Avidity Biosciences, Inc. announced that Arthur A. Levin, Ph.D. has been appointed to the board of directors of the company and is transitioning from chief scientific officer into the role of distinguished scientist and strategic leader, remaining a key member of Avidity's team. W. Michael Flanagan, Ph.D., has been promoted from chief technical officer to chief scientific and technical officer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.76 USD | -2.90% | +0.21% | +218.01% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+218.01% | 2.83B | |
-1.62% | 89.22B | |
+2.24% | 40.49B | |
-15.02% | 32.79B | |
+64.13% | 26.23B | |
-21.88% | 14.52B | |
-7.65% | 13.09B | |
-42.60% | 11.6B | |
-12.64% | 11.5B | |
+4.94% | 8.82B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Avidity Biosciences, Inc. Announces Changes to Its Board